Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy

This is a pharmacokinetic study (PK Study) to better understand empagliflozin dosing in pediatric Duchenne muscular dystrophy patients. Empagliflozin is currently used off-label in this population due to the mortality benefits seen in adult cardiomyopathy and heart failure. Investigators will perform PK studies in DMD patients of various ages and weights to better understand the PK profile (absorption, distribution, metabolism, excretion) and dosing to better treat Duchenne cardiomyopathy.

NCT Number	NCT07172971
Lead Sponsor	Vanderbilt University Medical Center Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Conditions	Duchenne Muscular Dystrophy (DMD)
Enrollment	10 participants
Start Date	2026-07-01
Primary Completion	2027-08-01 (estimated)
Study Completion	2028-02-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-21